GEN-1107
- Generic Name
- GEN-1107
PRO1107 in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Endometrial CancerTriple Negative Breast CancerNon-small Cell Lung CancerUrothelial CarcinomaOvarian CancerGastroEsophageal Cancer
- Interventions
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Genmab
- Target Recruit Count
- 280
- Registration Number
- NCT06171789
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath